Table 1. . Poly(ADP-ribose) polymerase inhibitors in clinical development for breast cancer.

PARP inhibitor	Pharmaceutical company	Investigational phase
Veliparib (ABT-888)	AbbVie	Phase III: – Neoadjuvant setting in combination with carboplatin/paclitaxel in triple-negative BRCA1/2-mutated metastatic breast cancer Phase II/III: – Combination therapy in germline BRCA1/2-mutated metastatic breast cancer
Olaparib (AZD2281)	AstraZeneca	Phase III: – Adjuvant treatment in germline BRCA1/2-mutated high-risk, HER2- primary breast cancer – Advanced setting monotherapy in germline BRCA1/2-mutated breast cancer
Niraparib (formerly MK-4827)	Tesaro	Phase III: – Advanced setting in germline HER-, BRCA1/2-mutated breast cancer
Talazoparib (BMN 673)	Medivation	Phase III: – Advanced setting monotherapy in germline BRCA1/2-mutated breast cancer Phase II: – Advanced setting BRCA1/2 wild-type, triple-negative breast cancer and homologous recombination deficiency – Advanced setting BRCA1/2-mutated breast cancer – Advanced setting in germline BRCA-intact breast cancer – Neoadjuvant setting in BRCA1/2-mutated breast cancer
Rucaparib (formerly AG 14699)	Clovis Oncology	Phase II: – Advanced setting in patients with known germline BRCA1/2-mutated solid tumors – Adjuvant setting in triple-negative breast cancer or germline BRCA1/2-mutated breast cancer
CEP-9722	Teva Pharmaceuticals Industries	Phase II: – Advanced setting in solid tumors

PARP: Poly(ADP-ribose) polymerase.

Adapted with permission from Livraghi et al. BMC Med. (2015) [12].